# Research Progress Update: Biological Countercurvature

**Date:** April 06, 2026
**To:** Principal Investigator
**From:** Research Program Manager / Comp Bio Team
**Subject:** Status Report & Roadmap to Submission

## 1. Executive Summary
The "Biological Countercurvature" project is well into Phase 2, moving toward clinical validation for Spine submission. The core theory (Information-Elasticity Coupling) and foundational simulation codebase (PyElastica bridge) are complete and validated via multiple computational experiments. The critical missing piece from previous sprints—the Cross-Species validation data—has been completed. The remaining bottlenecks involve connecting the abstract mathematical model parameters to explicit clinical proxies: mapping instability timing against peak height velocity (PHV), mapping model defect generation to clinical curve typologies (Lenke classification), and drafting the manuscript in a clinical IMRaD format.

## 2. Current State
- [x] **Theory**: IEC, Cosserat, and Kleiber scaling completed.
- [x] **Core Code**: `pyelastica_bridge.py` and core experimental runners are stable and generate core results.
- [x] **Validation (Pre-clinical)**: Toy Models A-E implemented and derisk theory.
- [x] **Data**: Cross-species dataset gathered (`DATA-01` completed).
- [ ] **Clinical Validation**: Pending mapping to clinical metrics (PHV, Lenke classes, sexual dimorphism).
- [ ] **Manuscript**: Transitioning to IMRaD format for *Spine*; "Clinical Relevance" section needed.

## 3. What's done
- `DATA-01`: Cross-Species Dataset completed.
- `DATA-02`: Mutation Parameter Mapping explicitly defined.
- `THEORY-01`: Physical Toy Models A-E created.
- `CODE-01` & `CODE-02`: Foundational physics models (Energy Deficit, Spinal Jetlag) running and mapped.
- Core script `experiment_cross_species_scaling.py` is operational.

## 4. What's in progress
- `CLIN-02`: Refining `toy_model_lenke_classes.py` to robustly predict Lenke 1-6 classifications.

## 5. Pending work (Top Prioritized)
1.  **[CLIN-01] PHV Timing Mapping**: Extract Peak Height Velocity data from literature and graph against model instability window. (Effort: 2 days, Risk: Low, Status: Pending)
2.  **[MS-01] IMRaD Restructuring**: Convert theory-dense draft into standard IMRaD sections. (Effort: 3 days, Risk: Medium, Status: Planned)
3.  **[CLIN-03] Sexual Dimorphism**: Map model parameters to female/male prevalence epidemiological data. (Effort: 1.5 days, Risk: Low, Status: Planned)
4.  **[MS-03] Figure Finalization (Clinical)**: Assemble "Clinical Translation" figures overlaying model predictions on patient cohort data. (Effort: 2 days, Risk: Medium, Status: Planned)

## 6. Experimental Results Summary

| Experiment | Setup | Metrics | Status | Reproducibility | Missing elements |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **EXP_CORE_01** (Minimal Elastica) | Cosserat rod + IEC | Curvature (S-curve) emergence | ✅ Done | `scripts/experiments/experiment_minimal_elastica.py` | None |
| **EXP_01a** (Energy Deficit Window) | $L$ vs Cost | $L_{crit} \approx 0.35$m | ✅ Done | `scripts/experiments/experiment_energy_deficit_window.py` | None |
| **EXP_01b** (Phase Diagram) | $L$ vs $\chi_\kappa$ | Instability region | ✅ Done | `scripts/experiment_energy_phase_diagram.py` | None |
| **EXP_02** (Spinal Jetlag) | Circadian mismatch & $g \to 0$ | Geometric drift | ✅ Done | `scripts/experiment_spinal_jetlag.py` | None |
| **EXP_06** (Cross-Species) | Validate cross-species scaling | $B_g$ cross-species curves | ✅ Done | `scripts/experiment_cross_species_scaling.py` | None |
| **CLIN_01** (PHV mapping) | Simulated deficit vs PHV Age | Timing | 🔴 Pending | `experiment_phv_timing.py` (Missing script) | Script, Literature Data |

## 7. Gaps to publication-quality evidence
- Missing script: `experiment_phv_timing.py` and the associated literature data to link $L_{crit}$ to adolescent growth spurts.
- Need structured mapping showing how $\chi_\kappa$ relates explicitly to curve progression velocity.

## 8. Proposed toy models + experiments
*(Note: Toy Models A-E are already completed. The following are proposed next-step pre-clinical / computational checks)*
1.  **Toy Model F (Sex Ratio Emulator):**
    *   **Objective**: Validate if minor parameter perturbations (representing estrogen-driven ligament laxity) naturally shift the instability onset, yielding the 7:1 ratio.
    *   **Method**: Run Monte Carlo ensemble of 1000 simplified 1D columns with varying stiffness distributions.
    *   **Success Metric**: Population distribution of failure modes matches epidemiological sex ratios.
    *   **Stop Condition**: Converged probability distribution curves.
2.  **Experiment: Anthropometric Sensitivity:**
    *   **Objective**: Confirm model robustly handles distinct BMI profiles without catastrophically failing.
    *   **Method**: Sweep cross-sectional radius $R$ vs length $L$ according to healthy and outlier BMI standard curves.
    *   **Success Metric**: Output curvature distributions remain bounded within plausible physiological limits.
    *   **Stop Condition**: Grid sweep complete over BMI range 15 to 30.

## 9. Timeline estimate + assumptions
- **Best Case:** 2.5 Weeks. Assumes PHV clinical literature is easily mappable to the simulation output timescale and IMRaD restructuring requires only minimal text rewrites.
- **Expected:** 4 Weeks. Allows 1.5 weeks for mapping model parameters (CLIN-01, CLIN-02) and 2.5 weeks for manuscript reformatting (MS-01, MS-03) and reviewing.
- **Worst Case:** 6 Weeks. If clinical alignment (e.g. sex ratios or PHV) inherently contradicts model predictions, necessitating minor theory recalibration and rerun of core simulations.

## 10. Risks + mitigations
- **Risk (Medium)**: Clinical Data Mismatch. Abstract physics parameters ($\chi_\kappa$) may not perfectly trace clinical metrics like Cobb angle progression.
  - *Mitigation*: Focus strictly on qualitative onset timing and relative scaling. Frame limitations clearly in Discussion.
- **Risk (High)**: IMRaD Reformatting Burden.
  - *Mitigation*: Offload complex math to an extensive Supplementary Material appendix.

## 11. Next 7 / 30 days plan

**Next 7 Days (Sprint):**
1.  **Days 1-2**: Conduct targeted literature search for Peak Height Velocity (PHV) cohort charts.
2.  **Days 3-4**: Complete `CLIN-02`: Finalize parameters for Lenke classification script.
3.  **Days 5-6**: Write `experiment_phv_timing.py` (CLIN-01) mapping model to extracted PHV data.
4.  **Day 7**: Update `docs/pending_work.md` and initiate MS-01 (IMRaD Restructuring).

**Next 30 Days:**
- **Weeks 2-3**: Complete IMRaD restructuring, generate final Clinical Translation figures (MS-03), and draft "Clinical Relevance" section (MS-02).
- **Week 4**: Final Internal Review of IMRaD version, targeted reference updates, and Pre-Submission checklist completion.
